Table 2 Cumulative adverse events during treatment by maximum grade per patient during treatment
Toxic effects, No. (%) | P value* | ||||
CCRT alone (n = 124) | CCRT + cetuximab(n = 62) | ||||
Grade 1 | Grade 2 | Grade 1 | Grade 2 | Grade 1–2 | |
Neutropenia | 34 (27.4%) | 49 (39.5%) | 16 (25.8%) | 18 (29.0%) | 0.107 |
Leucopenia | 36 (29.0%) | 24 (19.4%) | 17 (27.4%) | 13 (21.0%) | 1 |
Anemia | 44 (35.5%) | 23 (18.5%) | 3 (4.8%) | 5 (8.1%) | < 0.001 |
Thrombocytopenia | 19 (15.3%) | 10 (8.1%) | 5 (8.1%) | 3 (4.8%) | 0.091 |
AST increased | 17 (13.7%) | 3 (2.4%) | 9 (14.5%) | 1 (1.6%) | 1 |
ALT increased | 22 (17.7%) | 11 (8.9%) | 31 (50.0%) | 4 (6.5%) | < 0.001 |
BUN | 9 (7.3%) | 1 (0.8%) | 2 (3.2%) | 1 (1.6%) | 0.549 |
CRE | 13 (10.5%) | 0 | 2 (3.2%) | 0 | 0.087 |
Mucositis | 36 (29.0%) | 54 (43.5%) | 9 (14.5%) | 21 (33.9%) | 0.001 |
Dermatitis | 73 (58.9%) | 26 (21.0%) | 28 (45.2%) | 23 (37.1%) | 0.694 |
Vomiting | 47 (37.9%) | 17 (13.7%) | 35 (56.5%) | 11 (17.7%) | 0.003 |
Weight loss | 42 (36.8%) | 56 (49.1%) | 14 (23.7%) | 39 (66.1%) | 0.298 |
Acneiform rash | 0 (0.0%) | 0 (0.0%) | 31 (50.0%) | 15 (24.2%) | - |
Toxic effects, No. (%) | P value* | ||||
CCRT alone (n = 124) | CCRT + cetuximab(n = 62) | ||||
Grade 3 | Grade 4 | Grade 3 | Grade 4 | ||
Neutropenia | 18 (14.5%) | 1 (0.8%) | 8 (12.9) | 0 (0.0%) | 0.097 |
Leucopenia | 8 (6.5%) | 1 (0.8%) | 4 (6.5%) | 0 (0.0%) | 1 |
Anemia | 2 (1.6%) | 0 (0.0%) | 2 (3.2%) | 0 (0.0%) | 0.602 |
Thrombocytopenia | 4 (3.2%) | 1 (0.8%) | 1 (1.6%) | 0 (0.0%) | 0.665 |
AST increased | 0 | 0 | 0 | 0 | - |
ALT increased | 2 (1.6%) | 0 | 1 (1.6%) | 0 | 1 |
Renal impairment | 0 | 0 | 0 | 0 | - |
BUN | 0 | 0 | 0 | 0 | - |
CRE | 0 | 0 | 0 | 0 | - |
Mucositis | 29 (23.4%) | 0 (0.0%) | 29 (46.8%) | 3 (4.8%) | < 0.001 |
Dermatitis | 5 (4.0%) | 0 (0.0%) | 3 (4.8%) | 0 (0.0%) | 1 |
Vomiting | 2 (1.6%) | 0 (0.0%) | 2 (3.2%) | 1 (1.6%) | 0.335 |
Weight loss | 0 | - a | 2 (3.2%) | - a | 0.110 |